CFRX ContraFect Corporation

2.05
+0  (0%)
Previous Close 2.05
Open 1.90
Price To book 4.60
Market Cap 85.23M
Shares 41,578,000
Volume 114,671
Short Ratio 5.34
Av. Daily Volume 44,664

SEC filingsSee all SEC filings

  1. 8-K - Current report 161985537
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161984909
  3. 8-K - Current report 161889989
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161818048
  5. 8-K - Current report 161816650

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced January 6, 2017 that its Phase 2 trial initiation has been delayed until mid-2017. Previous guidance was for 4Q 2016.
CF-301
Serious infections caused byStaph aureus including MRSA

Latest News

  1. ContraFect Provides Program Update
  2. ContraFect Provides Program Update
  3. ContraFect to Present at Biotech Showcase 2017 Conference
  4. Is ContraFect Corp (CFRX) A Good Stock To Buy?
  5. ContraFect Corp. :CFRX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  6. Greenwood Hall Announces Appointment of Rubinstein, Sucoff, and Poutre to Board of Directors
  7. The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3
  8. ContraFect to Present at 28th Annual Piper Jaffray Healthcare Conference
  9. CONTRAFECT CORP Financials
  10. ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301
  11. CFRX: Preparations Continue for Launch of Phase 2 Clinical Trial of CF-301 in 4Q16…
  12. ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria
  13. ContraFect to Present at The Lysin Meeting
  14. CONTRAFECT CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  15. CONTRAFECT CORP Files SEC form 10-Q, Quarterly Report
  16. ContraFect Reports Third Quarter 2016 Financial Results and Provides Business Update
  17. ContraFect Reports Third Quarter 2016 Financial Results and Provides Business Update
  18. CONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers
  19. ContraFect Announces Organizational Changes
  20. ContraFect Announces Organizational Changes

SEC Filings

  1. 8-K - Current report 161985537
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161984909
  3. 8-K - Current report 161889989
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161818048
  5. 8-K - Current report 161816650
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 161797305
  7. 8-K - Current report 161785811
  8. 424B5 - Prospectus [Rule 424(b)(5)] 161781852
  9. FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses 161778559
  10. 8-K - Current report 161778016